Enochian BioSciences Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Enochian BioSciences's estimated annual revenue is currently $2.6M per year.(i)
  • Enochian BioSciences's estimated revenue per employee is $155,000

Employee Data

  • Enochian BioSciences has 17 Employees.(i)
  • Enochian BioSciences grew their employee count by -23% last year.

Enochian BioSciences's People

NameTitleEmail/Phone
1
Head Molecular BiologyReveal Email/Phone
2
SVP, Clinical OperationsReveal Email/Phone
3
CEO & DirectorReveal Email/Phone
4
Chief Financial Officer & Corporate SecretaryReveal Email/Phone
5
Director - Board DirectorsReveal Email/Phone
6
Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Enochian BioSciences?

Enochian BioSciences (formerly DanDrit Biotech USA Inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for HIV/AIDS and cancer. The company's lead candidate ENO-1001 (pre-IND) is a potentially sterilizing cure for HIV/AIDS. ENO-2001 is an HIV vaccine in preclinical stage, and its additional compounds ENO-4001 (phase three asset), ENO-4002, ENO-5001, and ENO-3001 are in discovery stages for prevention relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.

keywords:N/A

N/A

Total Funding

17

Number of Employees

$2.6M

Revenue (est)

-23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Enochian BioSciences News

2022-04-17 - Enochian BioSciences Announces the Appointment of ...

Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience.

2022-04-06 - Enochian BioSciences Announces Appointment of Senior ...

LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ: ENOB), a company focused on gene-modified cellular and...

2022-04-06 - Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit

LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.5M170%$104M
#2
$2.1M176%N/A
#3
$1.5M17N/AN/A
#4
$1.4M17N/AN/A
#5
$1.5M17N/AN/A